CZO recommended in the US!
Noble Capital Markets, Inc. Initiating Coverage. We are initiating research coverage on Ceapro, Inc. with an Outperform rating and $1.50 target price (corresponding to US$1.08 in US dollars). We value the Company using a risk-adjusted DCF model. We calculate a risk-adjusted equity value of $115 mm.